← ANALYST RATINGS · TIPRANKS
Korsana Biosciences (KRSA): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $52.33, the highest $70.00, the lowest $43.00. The average is +61.6% from the last price of $32.38.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $44.00 | Buy | +35.9% | Initiated | 05.10.26on TipRanks 07:07 | +0.1%next day +2.9% · 5 days +10.4% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $70.00 | Buy | +116.2% | Initiated | 28.09.26on TipRanks 06:40 | +0.2%next day +10.5% · 5 days −1.6% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Initiated | 14.09.26on TipRanks 05:45 | −0.5%next day +1.9% · 5 days +3.2% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $43.00 | Buy | +32.8% | Initiated | 14.09.26on TipRanks 05:00 | −0.5%next day +1.9% · 5 days +3.2% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $55.00 | Buy | +69.9% | Initiated | 11.09.26on TipRanks 04:45 | +29.1%next day −0.5% · 5 days +9.8% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Korsana Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 05.10.26: target $53.00 at a price of $30.49 (+73.8%); now: $53.00 at $32.38 (+63.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About Korsana Biosciences
- CEO: Jonathan Violin
- Employees: 1
- 221 Crescent Street, Waltham, MA, 02453, US
- korsana.com
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Data from the stock’s TipRanks forecast page, read 181 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗